Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646164 | 0.81 | GABRA1 (0.36) | DUTGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4784800 | 0.80 | DUT (0.31) | DUT | |
| SCHEMBL21166113 | 0.77 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22419991 | 0.72 | GABRA1 (0.32) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL25340611 | 0.72 | BACE1 (0.33) | DUT | |
| SCHEMBL15727502 | 0.72 | — | — | |
| SCHEMBL21459252 | 0.71 | CNR1 (0.35) | — | |
| SCHEMBL26140215 | 0.70 | DUT (0.39) | DUT | |
| SCHEMBL2653448 | 0.70 | CYP2C9 (0.46) | DUT | |
| SCHEMBL11890308 | 0.70 | HRH4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-112204036-B | Macrocyclic fused pyrazoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| WO-2021233397-A1 | PIPERAZINE CYCLIC UREAS | Sironax Ltd. (KY) | 2021-11-25 | — | — | WO | disclosed |
| CN-112204036-A | Macrocyclic fused pyrazoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-1150983-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047582-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| EP-0728752-A1 | Triazole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5405861-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0421210-A2 | Triazole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | DUT 2739/4885GABRA1 2730/4885GABRG2 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.